Introduction

Cachexia is a condition known as wasting disorder, which causes extreme weight loss and muscle wasting. It is a symptom of various chronic conditions, such as cancer, chronic renal failure, COPD, HIV or AIDS, and multiple sclerosis. The difference between cachexia and other types of weight loss is that it isn’t involuntary. People who developed cachexia, don’t lose weight because they’re trying to trim down with diet or exercise, but because they eat less due to a diversity of reasons. Simultaneously, their metabolism changes, which causes their body to break down too much muscle.

According to the research article published by Journal of Cachexia, Sarcopenia and Muscle, it is estimated that over 160,000 people in the United States visit the hospital with a cachexia diagnosis every year, with approximately 1.5–2 million cachexia-related deaths per year, across the globe. Several approaches to develop cachexia and muscle wasting treatments have failed to be successful in phase III clinical trials, but new approaches are currently in development. Given the high prevalence and very high mortality associated with cachexia, advances are urgently needed for patients worldwide.

Report Coverage

This report by Mordor Intelligence provides extensive insights into the current scenario and growth prospects of the market studied. Detailed graphical representations of the pipeline landscape, based on various phases, and the status of clinical trials, across major regions of the world, are given, with data obtained from multiple sources. The report also comprises a list of key sponsors with pipeline products for the concerned market.

Cachexia Clinical Trial Analysis by Phase and Status

• The clinical trial analysis for cachexia indicates that there are around XX number of trials under various phases
• Phase X trials accounted for the majority share
• The trial data analysis suggests a number of ongoing trials, as well as ones that have been terminated

Cachexia Clinical Trials Analysis, by Geography

• By geography, the scope of the report covers the regional assessment for clinical trials, globally. It covers concise information regarding registered clinical trials in different countries, across several developed and emerging markets
• In the modern industrialized world, the overall prevalence of cachexia is increasing, with the growth of chronic illness prevalence, and it is estimated that, it currently affects approximately 0.5–1.0% of the world population, i.e. around 6–12 million people

Key Sponsors in Cachexia Clinical Trials

The report will cover analysis on trails and information on key sponsors, companies, and researchers.

Research Methodology

Our data collection team builds scientific research models, based on data sourced from various internal databases, primary and secondary researches, and our in-house team of research experts. The pipeline assessment reports are generated based on information procured from various stakeholders, such as sponsors, clinical trial organizations, pharmaceutical companies, government bodies, trade agencies, industry journals, scientific literature databases, investor reports, press release statements, and several other sources. The data generated using secondary research and primary research is validated through discussions with industry KOL’s and C-suite executives. The data presented in the reports is continuously updated to incorporate the most relevant and authentic information to our clients.

Reasons to buy the Report

This report will help you to understand

• The number of clinical trials that are being conducted worldwide
• The key products under development (Phase I, Phase II, and Phase III)
• The main areas of research under development (by product, mechanism of action, molecule, delivery, etc.)
• The average recruitment size in trials
• Key deals between institutions and industries
• Insights on regional- and country-level data
• Dormant and discontinued studies across the category
• Information on key sponsors and profiles
• Protocol and design comparisons, to generate the best solution for your product development strategy